Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Genome‐wide association studies of survival in 1520 cancer patients treated with bevacizumab‐containing regimens

International Journal of Cancer(2021)10.1002/ijc.33810Source: DataRank Database

Genome‐wide association studies of survival in 1520 cancer patients treated with bevacizumab‐containing regimens is a research paper published in International Journal of Cancer (2021). On theSindex it has a DataRank of 0. It has been cited 10 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access10 citations

Download PDF

Cite:

Linked data & code

refsnp nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (16 grants)Impact (FWCI 1.42)OA: bronzeTopics (57)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (17)

Jin Wang ORCID,Alexander B. Sibley ORCID,Wei Xu ORCID,Osvaldo Espin‐Garcia ORCID,Chen Jiang ORCID

Live enrichment

PubMed:34528705 PMC:PMC8627468 OpenAlex:https://openalex.org/W3199603721

Fundação de Amparo à Pesquisa do Estado de São Paulo

Grant: 2018/04491‐2

National Cancer Institute

Grant: U10CA180821

National Cancer Institute

Grant: U10CA180863

National Cancer Institute

Grant: U10CA180882

National Cancer Institute

Grant: U10CA180888

National Cancer Institute

Grant: U24CA196171

National Cancer Institute

Grant: UG1CA233180

National Cancer Institute

Grant: UG1CA233253

National Cancer Institute

Grant: UG1CA233290

National Cancer Institute

Grant: UG1CA233327

National Cancer Institute

Grant: UG1CA233373

Pfizer

Grant: CALGB 80405

NHGRI NIH HHS

Grant: R01 HG009974

NCI NIH HHS

Grant: P50 CA058223

Genentech

Bristol-Myers Squibb

FWCI

1.42

Citation Percentile

0.8%

Citation Trend

2021

2022

2023

2024

bronzeLicense: http://onlinelibrary.wiley.com/termsAndConditions#vor

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.33810

BRONZEhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.33810

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.33810

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33810

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/ijc.33810

Fields of Study

Genetic factors in colorectal cancerColorectal Cancer Treatments and StudiesCholangiocarcinoma and Gallbladder Cancer StudiesMedicineAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBiomarkers, TumorCarboplatinCetuximabFemaleFollow-Up StudiesGenome-Wide Association StudyHumansMaleMiddle AgedNeoplasmsPaclitaxelPrognosisSurvival Rate

MeSH Terms

BevacizumabCetuximabAntineoplastic Combined Chemotherapy ProtocolsFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasmsPrognosisBiomarkers, TumorSurvival RateCarboplatinPaclitaxelGenome-Wide Association Study

Keywords

BevacizumabMedicineInternal medicineOncologyHazard ratioGenome-wide association studySingle-nucleotide polymorphismColorectal cancerMeta-analysisProportional hazards modelConfidence intervalOvarian cancerSNPCancerChemotherapyGenotypeBiologyGeneticsGeneOverall SurvivalBard1Prune2Agap1

Sustainable Development Goals

SDG 0: Good health and well-being